New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2013
05:55 EDTDVA, DVA, WLP, WLP, MCK, MCK, CI, CI, BMY, BMY, MDT, MDT, COV, COV, BAYRY, BAYRY, EPOC, EPOC, AET, AET, AGN, AGN, HUM, HUM, BDX, BDXWharton School of Business to host a conference
19th Annual Wharton Healthcare Business Conference is being held in Philadelphia on February 14-15.
News For DVA;HUM;AGN;AET;EPOC;BAYRY;COV;MDT;BMY;CI;MCK;WLP;BDX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
April 17, 2015
09:41 EDTBMYBristol-Myers up after Phase III Opdivo study met endpoint, trial stopped early
Subscribe for More Information
09:36 EDTBMYActive equity options trading on open
Subscribe for More Information
09:08 EDTBMYBristol-Myers data should be positive, says SunTrust
SunTrust expects the AACR data for Bristol-Myers' CheckMate-069 Opdivo + Yervoy combo, a treatment for melanoma, to show a positive overall response rate and progressive free survival that exceeds its prior -0004 results. The firm notes that the data is due to be presented on April 20. It raised its 2020 Opdivo revenue estimate to $7.1B versus the Street's $6.9B and raised its price target o n he stock to $74 from $70 while keeping a Buy rating on the shares.
08:58 EDTBMYBristol-Myers jumps 4% after Opdivo study stopped early after meeting endpoint
Subscribe for More Information
08:56 EDTBMYBristol-Myers says Phase III Opdivo study met endpoint, trial stopped early
Subscribe for More Information
07:10 EDTMDTMedtronic's Solitaire improved neurological outcomes in stroke patients in trial
Subscribe for More Information
April 16, 2015
12:19 EDTBAYRYBayer downgraded to Equal Weight from Overweight at Morgan Stanley
Subscribe for More Information
12:16 EDTBMYEli Lilly and Bristol-Myers restructure Erbitux collaboration in N. America
Subscribe for More Information
10:04 EDTMCKHigh option volume stocks
Subscribe for More Information
08:59 EDTBMYGene therapy companies could benefit from increased attention, says Roth Capital
Subscribe for More Information
07:05 EDTMCKNovaBay signs distribution agremeent with AmerisourceBergen
Subscribe for More Information
April 15, 2015
12:01 EDTBDXBecton Dickinson price target raised to $167 from $160 at Piper Jaffray
Subscribe for More Information
10:36 EDTMCKBofA/Merrill U.S. credit analysts hold an analyst/industry conference call
Subscribe for More Information
10:01 EDTDVADaVita sees taking $250M reserve for Vanier litigation
In a regulatory filing yesterday related to a bond offering, DaVita noted it has received subpoenas or other requests for documents from the federal government in connection with the Vainer private civil suit, the Swoben private civil suit, the 2011 U.S. Attorney Medicaid investigation, the 2015 U.S. Attorney Transportation Investigation and the JSA investigation. In each of the Vainer and Swoben private civil suits, a relator filed a complaint against the company in federal court under the qui tam provisions of the False Claims Act and pursued the claims independently after the government declined to intervene. With regard to the Vanier private civil suit, the parties are engaged in active litigation. The parties in that suit completed discovery in early 2014; however, in August 2014, the court granted relators’ motion for sanctions and reopened discovery on a limited basis. The court in Vainer is considering the plaintiffs’ request for further sanctions, which could result in a range of outcomes from no other sanctions to plaintiffs’ request to strike our answer. Certain of these sanctions could materially adversely impact the company's ability to defend the case, DaVita said. "While we cannot predict the ultimate outcome of this case, if the case is resolved in favor of the plaintiffs, its resolution could have a material adverse effect on our earnings and cash flows. We recently commenced settlement discussions with the plaintiffs in Vainer." The company said it expects to accrue an estimated loss contingency reserve of $250M related to this matter. "Negotiations are ongoing and we can make no assurances as to whether the Vainer suit will settle and, if it does settle, whether it will settle for an amount higher than the current reserve," DaVita added. With regard to the Swoben private civil suit, in July 2013, the court granted HCP’s motion and dismissed with prejudice all of the claims in the Third Amended Complaint, and in October 2013 the plaintiff filed an appeal of the dismissal, which is currently pending.
09:08 EDTBMYOn The Fly: Pre-market Movers
Subscribe for More Information
07:41 EDTBMY, BAYRYEBD Group to hold a forum
ChinaBio Partnering Forum 2015 is being held in Shanghai, China on April 15-16.
07:03 EDTBMYLexicon and Bristol-Myers select development candidate for neuropathic pain
Subscribe for More Information
April 14, 2015
12:13 EDTDVADaVita announces $725.94M repurchase program
Subscribe for More Information
11:04 EDTMDTMedtronic to develop stent graft system under patent agreement with Sanford
Subscribe for More Information
09:16 EDTMDTMedtronic announces CE Mark for Micra TPS
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use